Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322566 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
A Phase 2 study of Lung Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
- 20
- Study locations
NCT03322566: Completed Phase 2 study of Lung Cancer, sponsored by Incyte Corporation.
NCT03322566 is a Phase 2 study of Lung Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 233 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03322566, a Phase 2 study of Lung Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).
Primary Outcome
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) based on blinded independent central review (BICR).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Epacadostat
- DRUG Platinum-based chemotherapy
Study Locations (20)
Florida
- Lynn Cancer Institute - Boca Raton
- Florida Cancer Specialists (South Region) - Fort Myers
- Florida Cancer Specialists (North Region) - St. Petersburg
Arizona
- Western Regional Medical Center, Inc. - Goodyear
- Arizona Oncology Associates PC- HOPE - Tucson
Pennsylvania
- St. Luke's Hospital - Anderson Campus - Easton
- Allegheny General Hospital - Pittsburgh
Tennessee
- Tennessee Oncology, PLLC/The Sarah Cannon Research Institute - Chattanooga
- Tennessee Oncology, PLLC/The Sarah Cannon Research Institute - Nashville
Virginia
- Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care - Blacksburg
- Emily Couric Clinical Cancer Center - Charlottesville
Alabama
- Southern Cancer Center, PC - Daphne
Indiana
- PPG-Oncology - Fort Wayne
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 2 |
What the finished NCT03322566 record still lists
NCT03322566 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03322566 names 20 study sites across 14 states, led by Florida, Arizona, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03322566 about?
NCT03322566 is a clinical study titled "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)". The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03322566?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2018-01-09. Estimated completion is 2020-10-16.
What conditions does trial NCT03322566 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT03322566?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Epacadostat (DRUG), Platinum-based chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03322566?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03322566 being conducted?
This trial has 20 study locations across Alabama, Arizona, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03322566's enrollment target sits among peer trials
233 122nd of 409 higher than 288 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI